Best Practice & Research Clinical Haematology

Papers
(The TQCC of Best Practice & Research Clinical Haematology is 5. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-06-01 to 2025-06-01.)
ArticleCitations
Contemporary and future strategies in polycythemia vera50
HLA typing: A review of methodologies and clinical impact on haematopoietic cell transplantation28
The role of randomized controlled trials, registries, observational databases in evaluating new interventions21
Asparaginase dosing for obese patients with acute lymphoblastic leukemia and factors that contribute to outcomes19
Reducing barriers of access and care related to hematopoietic cell transplantation and cellular therapy: The mission-driven role of the national marrow donor program18
Allogeneic “Off-the-Shelf” CAR T cells: Challenges and advances17
“The state of the science” of childhood, adolescent and young adult Non Hodgkin Lymphoma (NHL)17
Coagulopathy in COVID-19 and anticoagulation clinical trials17
What are the long-term complications of pediatric ALL treatments and how can they be mitigated? Perspectives on long-term consequences of curative treatment in childhood ALL16
Endpoint selection and evaluation in hematology studies16
Editorial Board16
Take a spin: Apheresis in the care of adult leukaemia patients15
Vaccine-induced immune thrombotic thrombocytopenia14
The presentation of results from studies in clinical haematology14
Advances in CAR design14
Targeted cellular therapy for treatment of relapsed or refractory leukemia13
Creating a GMP cell processing program: A focus on quality and regulation13
Accelerated and blast phase myeloproliferative neoplasms13
Blood coagulation and cancer genes13
Diagnosis and management of post-transplant lymphoproliferative disease following solid organ transplantation in children, adolescents, and young adults11
Biopathology of childhood, adolescent and young adult non-Hodgkin lymphoma11
Principles of cost-effectiveness studies and their use in haematology10
GATA2 and marrow failure10
How can we improve response assessments in MDS? Strategies to improve response assessment in MDS treatment paradigms10
Dysregulation of Protein S in COVID-199
Cytogenomics of B-cell non-Hodgkin lymphomas: The “old” meets the “new”9
Cancer associated thrombosis in pediatric patients9
Bone marrow transplantation for acquired aplastic anemia: What's new9
Applications and prospects of molecularly targeted drugs combined with CAR-T cell therapy to treat multiple myeloma9
Editorial Board8
The international cooperative Gaucher group (ICCG) Gaucher registry8
The role of registries in hematological disorders8
What should be done and what should be avoided when comparing two treatments?8
Addressing symptom burden in myeloproliferative neoplasms7
Worldwide sources of data in haematology: Importance of clinician-biostatistician collaboration7
Prevention and treatment of COVID-19 in patients with benign and malignant blood disorders7
How predictive is the finding of clonal hematopoiesis for the development of myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML)?7
Is HLA-E with its receptors an immune checkpoint or an antigenic determinant in allo-HCT?7
Clinical experience of CAR T cells for multiple myeloma7
Late effects and frontline treatment selection for children with non-Hodgkin lymphoma7
Anti-GM-CSF autoantibodies in myeloid leukemias6
Hodgkin Lymphoma: A disease shaped by the tumor micro- and macroenvironment6
Cytokines in hematopoietic cell transplantation and related cellular therapies6
The analysis of multiple outcomes, multiple variables and variables selection in hematopoietic cell transplantation studies6
Handling missing covariate data in clinical studies in haematology6
Challenges in anticoagulation for patients with brain tumors6
Human mesenchymal stem cell therapy: Potential advances for reducing cystic fibrosis infection and organ inflammation6
Thrombosis and bleeding in hematological malignancy6
Editorial Board / Aims & Scope6
Relevance of donor-specific HLA antibodies in hematopoietic cell transplantation5
Advances in polycythemia vera and lessons for acute leukemia5
The current landscape: Allogeneic hematopoietic stem cell transplant for acute lymphoblastic leukemia5
The most frequent HLA alleles around the world: A fundamental synopsis5
Preface5
CAR assembly line: Taking CAR T-cell manufacturing to the next level5
Thrombopoietin receptor agonists for marrow failure: A concise clinical review5
A reflection on Arnold Caplan, the father of MSC5
What is relative survival and what is its role in haematology?5
What is the role of the bone marrow microenvironment in AML?5
Recent progress in acute leukemia and myelodysplasia5
Corrigendum to “Endpoint selection and evaluation in hematology studies” [Best Pract Res Clin Haematol 36 (2023) 101479]5
0.043606042861938